Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.41 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.41 |
| ▸ | ACLY | P53396 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9835205 | 0.87 | ALDH1A1 (0.50) | ALDH1A1CHRM1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL9826471 | 0.85 | ACLY (0.50) | ALDH1A1CHRM1SMN1; SMN2TSHRACLY | |
| SCHEMBL1342767 | 0.83 | ACLY (0.38) | CHRM1SMN1; SMN2TSHRACLYGAA | |
| SCHEMBL25321844 | 0.80 | ACLY (0.39) | ALDH1A1CHRM1SMN1; SMN2TSHRACLY | |
| SCHEMBL5796159 | 0.80 | ALDH1A1 (0.41) | ALDH1A1CHRM1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL2867405 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CHRM1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL4229823 | 0.78 | ALDH1A1 (0.48) | ALDH1A1CHRM1CHRM5CHRM3SMN1; SMN2 | |
| SCHEMBL5526119 | 0.78 | ACLY (0.45) | ALDH1A1CHRM1SMN1; SMN2TSHRACLY | |
| Ammonia Solution, Strong SCHEMBL19133680 | 0.78 | THRB (0.47) | ALDH1A1CHRM1SMN1; SMN2TSHRACLY | |
| Hydrochloric Acid SCHEMBL864764 | 0.76 | ACLY (0.43) | ALDH1A1CHRM1SMN1; SMN2TSHRACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2727915-B1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | CONCERT PHARMACEUTICALS INC (US) | 2016-04-13 | — | — | EP | claimed |
| EP-2727915-A1 | Synthesis of deuterated catechols and benzo[d][1,3]dioxoles and derivatives thereof | Concert Pharmaceuticals Inc. (US) | 2014-05-07 | — | — | EP | claimed |
| WO-2012138698-A1 | SYNTHESIS OF BETA-MANNURONIC ACID OLIGOSACCHARIDES | ANCORA PHARMACEUTICALS INC. (US) | 2012-10-11 | — | — | WO | claimed |
| EP-4604951-A1 | 1-(SULFONYL)-N-PHENYLPYRROLIDINE-2-CARBOXAMIDES DERIVATIVES AND USE THEREOF | AMIRA THERAPEUTICS, S.L. (ES) | 2025-08-27 | — | — | EP | disclosed |
| EP-4419513-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2025-08-27 | — | — | EP | disclosed |
| US-12384800-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2025-08-12 | — | — | US | disclosed |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-07-31 | — | — | US | disclosed |
| WO-2025077996-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2025-04-17 | — | — | WO | disclosed |
| WO-2025050647-A1 | IONIZABLE CATIONIC LIPID COMPOUNDS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 晟迪生物医药(苏州)有限公司 | 2025-03-13 | — | — | WO | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| CN-110621678-B | Antitumor compounds | 法马马有限公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-2032551-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-03-11 | — | — | EP | disclosed |
| WO-2009017671-A1 | SYNTHESIS OF INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007144423-A1 | ANTITUMORAL DIHYDROPYRAN-2-ONE COMPOUNDS | PHARMA MAR, S.A. (ES) | 2007-12-21 | — | — | WO | disclosed |
| WO-2006042200-A2 | METHOD FOR SYNTHESIS OF BETA-GLUCANS | EAST TENNESSEE STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-0211416-B1 | NOVEL HMG-COA REDUCTASE INHIBITORS | MERCK & CO. INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4851436-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | MERCK & CO., INC. (US) | 1989-07-25 | — | — | US | disclosed |
| US-4668699-A | 6-(NAPHTHYLETHYL)TETRAHYDROPYRAN-2-ONES; ANTILIPEMIC, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| US-4665091-A | 3-HYDROXY-3-METHYLGLUTARYL-COENZYME A, ANTICHOLESTEROL | MERCK & CO., INC. (US) | 1987-05-12 | — | — | US | disclosed |
| EP-0211416-A2 | Novel HMG-CoA reductase inhibitors | MERCK & CO. INC. (US) | 1987-02-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384800-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | ALDH1A1 144/4885CHRM1 4848/4885CHRM5 4829/4885 |
| US-20250243174-A1 | ANTITUMORAL COMPOUNDS | MCL1, XPOT, GZMB | ALDH1A1 318/4885CHRM1 4676/4885CHRM5 4809/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | ALDH1A1 795/4885CHRM1 4854/4885CHRM5 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.